Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technology. Intellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex vivo and in vivo approaches.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/18/14 | $15,000,000 | Series A |
Atlas Venture Novartis Venture Funds | undisclosed |
| 09/01/15 | $70,000,000 | Series B |
Atlas Venture EcoR1 Capital Fidelity Management & Research Company Foresite Capital Janus Capital Novartis Venture Funds OrbiMed HealthCare Fund Management Sectoral Asset Management | undisclosed |
